For instance, LD IL-10 and anti-IL1-α antibodies demonstrate promise in colitis [99] and osteoarthritis models [100], while a combination of IL-4, IL-10, and anti-IL1-α antibodies outperforms DMARDs in rheumatoid arthritis [101]. This evidence concerns the gene IL10 and rheumatoid arthritis.